A HIGHLY IMMUNOGENIC TUMOR TRANSFECTED WITH A MURINE TRANSFORMING GROWTH-FACTOR TYPE-BETA-1 CDNA ESCAPES IMMUNE SURVEILLANCE

被引:371
作者
TORREAMIONE, G [1 ]
BEAUCHAMP, RD [1 ]
KOEPPEN, H [1 ]
PARK, BH [1 ]
SCHREIBER, H [1 ]
MOSES, HL [1 ]
ROWLEY, DA [1 ]
机构
[1] UNIV VANDERBILT,DEPT CELL BIOL,NASHVILLE,TN 37237
关键词
immunosuppression; tumor progression;
D O I
10.1073/pnas.87.4.1486
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A highly immunogenic C3H-derived UV-induced tumor was cotransfected with a murine transforming growth factor type β1 (TGF-β1) cDNA and a neomycin-resistance gene. Stable clones were isolated and used in vitro and in vivo to determine the effects of endogenously produced TGF-β on cytolytic T-lymphocyte (CTL) responses. Tumor cells producing TGF-β, though retaining expression for class I major histocompatibility complex molecules and the tumor-specific antigen, did not stimulate primary CTL responses in vitro and were not effective in vivo for directly stimulating primary CTL or in priming for CTL responses. Furthermore, TGF-β-producing tumors grew progressively in transiently immunosuppressed mice without losing the tumor antigen; thus, TGF-β produced by tumors may promote escape from immune surveillance.
引用
收藏
页码:1486 / 1490
页数:5
相关论文
共 31 条
  • [1] PARTIAL CHARACTERIZATION OF CYTOTOXIC-CELLS INFILTRATING SPONGE MATRIX ALLOGRAFTS
    ASCHER, NL
    FERGUSON, RM
    HOFFMAN, R
    SIMMONS, RL
    [J]. TRANSPLANTATION, 1979, 27 (04) : 254 - 259
  • [2] CONSTRUCTION AND APPLICATIONS OF A HIGHLY TRANSMISSIBLE MURINE RETROVIRUS SHUTTLE VECTOR
    CEPKO, CL
    ROBERTS, BE
    MULLIGAN, RC
    [J]. CELL, 1984, 37 (03) : 1053 - 1062
  • [3] SERUM CONTAINS A PLATELET-DERIVED TRANSFORMING GROWTH-FACTOR
    CHILDS, CB
    PROPER, JA
    TUCKER, RF
    MOSES, HL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (17): : 5312 - 5316
  • [4] CLARK DA, 1988, J IMMUNOL, V141, P3833
  • [5] COFFEY RJ, 1988, CANCER RES, V48, P1596
  • [6] CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217
  • [7] DERYNCK R, 1986, J BIOL CHEM, V261, P4377
  • [8] ESPEVIK T, 1988, J IMMUNOL, V140, P2312
  • [9] GILBERTSON SM, 1986, J IMMUNOL, V136, P3567
  • [10] HIRSCH R, 1988, J IMMUNOL, V140, P3766